Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 11/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5904151 | 0.84 | NPSR1 (0.52) | SLC6A4CNR1FFAR4GSTP1C5AR1 | |
| SCHEMBL6069616 | 0.81 | PTGS2 (0.55) | PTGER1 | |
| SCHEMBL6069619 | 0.74 | PTGER1 (0.48) | SLC6A4PTGER1 | |
| SCHEMBL5109364 | 0.74 | SLC6A4 (0.50) | SLC6A4CNR1PLAUPTGER1 | |
| SCHEMBL5775335 | 0.73 | GSK3B (0.38) | — | |
| SCHEMBL28631630 | 0.71 | MAP4K4 (0.47) | — | |
| SCHEMBL5773780 | 0.71 | ALDH1A1 (0.37) | — | |
| SCHEMBL2287859 | 0.71 | SLC6A4 (0.56) | SLC6A4CNR1PLAU | |
| SCHEMBL4154373 | 0.71 | SLC6A4 (0.56) | SLC6A4CNR1PLAU | |
| SCHEMBL29837500 | 0.71 | SLC6A4 (0.56) | SLC6A4CNR1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | disclosed |
| EP-1592666-A1 | 2,3 -BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004072037-A1 | 2,3'-BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | PTGS2, PTGES2, PTGER2 | SLC6A4 2410/4885CNR1 503/4885PLAU 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.